Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.45 |
| ▸ | CA2 | P00918 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2677653 | 0.86 | EPHX2 (0.51) | — | |
| SCHEMBL1999900 | 0.84 | ALDH1A1 (0.48) | CA1CA2MEN1KMT2AGAA | |
| SCHEMBL23299308 | 0.83 | EPHX2 (0.44) | — | |
| Trifluoroacetic Acid SCHEMBL3170178 | 0.82 | CA2 (0.44) | CA2MEN1KMT2A | |
| SCHEMBL29997545 | 0.81 | EPHX2 (0.41) | GAAKDM4EGLAMAPTHPGD | |
| SCHEMBL3170771 | 0.81 | SCN5A (0.53) | CA1CA2 | |
| SCHEMBL10241525 | 0.80 | TDP1 (0.48) | CA1CA2MEN1KMT2AALDH1A1 | |
| SCHEMBL2678579 | 0.80 | TDP1 (0.48) | CA1CA2MEN1KMT2AALDH1A1 | |
| SCHEMBL5200736 | 0.80 | ALDH1A1 (0.45) | CA1CA2MEN1KMT2AGAA | |
| SCHEMBL3167587 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7645792-B2 | Prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. (US) | 2010-01-12 | — | — | US | disclosed |
| US-20090005352-A1 | Prodrugs of Propofol, Compositions and Uses Thereof | XENOPORT, INC. (US) | 2009-01-01 | — | — | US | disclosed |
| US-7241807-B2 | Prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. (US) | 2007-07-10 | — | — | US | disclosed |
| US-20060041011-A1 | Prodrugs of propofol, compositions and uses thereof | XENOPORT, INC. | 2006-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060041011-A1 | Prodrugs of propofol, compositions and uses thereof | CYP2C19, CYP3A5, CYP3A4 | CA1 1129/4885CA2 1444/4885MEN1 370/4885 |
| US-20090005352-A1 | Prodrugs of Propofol, Compositions and Uses Thereof | CYP2C19, CYP3A5, CYP3A4 | CA1 1129/4885CA2 1444/4885MEN1 370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.